Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 7/31/2025

Acute Congestive Heart Failure Management

Initial Treatment

  • The European Society of Cardiology recommends furosemide 40 mg IV bolus (or equivalent to oral home dose if on chronic therapy) as the initial treatment for acute CHF exacerbation to rapidly reduce fluid overload and relieve congestion 1
  • For patients already on chronic oral diuretic therapy, the initial IV dose should be at least equivalent to their oral dose, as suggested by the American Journal of Kidney Diseases 2
  • Non-invasive ventilation (NIV) should be started promptly in patients with acute pulmonary edema showing respiratory distress, according to the European Journal of Heart Failure 1
  • CPAP is feasible in pre-hospital settings; PS-PEEP preferred for patients with acidosis/hypercapnia, as recommended by the European Journal of Heart Failure 1
  • Initial IV furosemide dose should be 20-40 mg IV bolus (or equivalent), with a total dose remaining <100 mg in the first 6 hours and <240 mg during the first 24 hours 3
  • Alternative loop diuretics include bumetanide (0.5-1.0 mg) or torsemide (10-20 mg) 4, 5

Vasodilator Therapy

  • IV nitrates are recommended for patients with normal to high blood pressure, as suggested by the European Journal of Heart Failure 1
  • Vasodilators should be avoided in patients with SBP <110 mmHg, according to the European Journal of Heart Failure 1

Management of Inadequate Diuretic Response

  • The American Journal of Kidney Diseases recommends increasing the loop diuretic dose or considering combination therapy with thiazide diuretic (e.g., metolazone or hydrochlorothiazide) for inadequate diuretic response 2
  • Switching to continuous infusion of loop diuretic is also an option, as suggested by the American Journal of Kidney Diseases 2
  • When initial diuretic response is inadequate, consider increasing the loop diuretic dose, adding a second diuretic (such as metolazone or hydrochlorothiazide), or using continuous infusion of loop diuretic 4, 5, 3

Hypotension Management

  • The European Heart Journal defines hypotension as SBP <90 mmHg despite adequate filling status with signs of hypoperfusion, and recommends fluid challenge (>200 mL over 15-30 min) if no overt fluid overload 6
  • Dobutamine may be used to increase cardiac output, as suggested by the European Heart Journal 6
  • Vasopressors (preferably norepinephrine over dopamine) should only be used if strictly needed to maintain systolic BP with persistent hypoperfusion, according to the European Heart Journal 6
  • If hypotension develops, consider temporarily reducing vasodilators while maintaining diuresis 7

Sequential Nephron Blockade

  • The American Journal of Kidney Diseases recommends considering sequential nephron blockade by adding thiazide diuretic to loop diuretic 2
  • Acetazolamide may be used to inhibit proximal tubule sodium reabsorption, as suggested by the American Journal of Kidney Diseases 2
  • Administering loop diuretic twice daily or on an empty stomach is also an option, according to the European Journal of Heart Failure 7
  • Short-term IV infusion of loop diuretic may be considered, as recommended by the European Journal of Heart Failure 7

Chronic Medication Management

  • The European Journal of Heart Failure recommends continuing ACE inhibitors/ARBs unless the patient is hemodynamically unstable or has significant renal dysfunction, and considering dose reduction if symptomatic hypotension develops 7
  • Beta-blockers should be continued in stable patients, with consideration of dose reduction (halve dose) if increasing congestion or marked fatigue, as suggested by the European Journal of Heart Failure 7
  • Mineralocorticoid receptor antagonists (MRAs) should be continued unless contraindicated (significant hyperkalemia or renal dysfunction), according to the European Journal of Heart Failure 7
  • ACE inhibitors and ARBs should be continued in most patients unless hemodynamically unstable or contraindicated 3
  • Beta-blockers should be continued in stable patients, but may need temporary dose reduction if significant volume overload 3, 7
  • Mineralocorticoid receptor antagonists (MRAs) should be continued unless contraindicated 8

Avoiding Harmful Therapies

  • The European Journal of Heart Failure recommends avoiding routine use of opioids in AHF patients, as they may be associated with higher rates of mechanical ventilation, ICU admission, and death 1
  • Vasopressors and sympathomimetics should be avoided except in cardiogenic shock, as recommended by the European Journal of Heart Failure 1

Monitoring and Discharge

  • Monitor response to diuretic therapy through daily weight measurements, fluid intake/output tracking, clinical signs of congestion, vital signs, and electrolytes, BUN, and creatinine daily during active diuresis 3
  • The European Journal of Heart Failure recommends monitoring for electrolyte abnormalities, such as hypokalemia/hypomagnesemia, and considering supplements or adjusting medication doses accordingly 7
  • Hyperkalemia should be managed by reducing or stopping MRA and monitoring closely, as suggested by the European Journal of Heart Failure 7
  • Invasive hemodynamic monitoring is indicated when the patient is in respiratory distress, has clinical evidence of impaired perfusion, or uncertainty about adequacy of intracardiac filling pressures 3
  • Transition from IV to oral diuretics with careful attention to oral diuretic dosing and electrolyte monitoring 3
  • Optimize guideline-directed medical therapy (GDMT) before discharge, including initiation or uptitration of ACE inhibitors/ARBs and beta-blockers in stable patients 3
  • Provide comprehensive discharge instructions, including medication regimen, daily weight monitoring, dietary sodium restriction, activity recommendations, follow-up appointments, and instructions on what to do if symptoms worsen 3

Potential Pitfalls

  • Excessive diuresis can lead to hypotension, worsening renal function, and electrolyte abnormalities
  • Premature discontinuation of chronic HF medications, such as ACE inhibitors/ARBs and beta-blockers, can worsen long-term outcomes 3
  • Inadequate monitoring of electrolytes, renal function, and clinical status during active diuresis can lead to poor outcomes
  • Insufficient diuresis can lead to persistent congestion and poor outcomes, and intensification of the diuretic regimen should not be delayed when response is inadequate 4, 3

REFERENCES

2
8

Heart Failure Management [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025